

Cullen G. Taylor

Partner

Northern Virginia

Biography

Cullen Taylor helps life sciences companies structure and negotiate their most complex agreements, particularly those involving the development, acquisition, and commercialization of intellectual property and technology. Cullen takes a practical, results-oriented approach to transactions, drawing on his broad experience to anticipate and address problems before they arise.

Cullen understands the legal and commercial risks that arise as parties enter, live under, and exit long-term partnering arrangements. Cullen is skilled at structuring and drafting contracts that address these concerns while keeping the client's business goals at front and center.

Cullen handles a variety of transactions within the life sciences industry, including product acquisition, licensing, research and development, collaboration, co-promotion, supply, and distribution agreements. His clients include pharmaceutical and biotechnology companies and device and diagnostics manufacturers with products and therapies at all stages of development. Cullen is often called upon to advise such clients on discovering, developing, and acquiring cutting-edge therapies and innovative technologies.

Cullen is head of the firm's Life Sciences Licensing and Commercial Transactions team. He regularly collaborates with his colleagues in the firm's Corporate and Regulatory practices to address intellectual property and technology-related issues that arise in



Phone

+1 703 610 6177

Fax

+1 703 610 6200

Email

cullen.taylor@hoganlovells.com

Languages

English
Spanish

Practices

Commercial
Complex Contracting
Intellectual Property
IP and Technology Transactions

Industries

Life Sciences and Health Care
Technology and Telecoms

Areas of focus

corporate transactions and in the product approval process, and has advised a number of clients on licensing matters in relation to the recently implemented Inflation Reduction Act.

Cullen was recognized by Managing IP as the 2021 IP Transactional Lawyer of the Year for the Americas.

Representative experience

Representing Gilead Sciences in its collaboration with Dragonfly Therapeutics to develop and commercialize natural killer cell engagers in oncology and inflammation.

Representing Daiichi Sankyo in its collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo's DS-1062, a potential treatment for multiple tumor types.

Represented Modex Therapeutics in its license and research collaboration with a multinational pharmaceutical company for the development of MDX-2201, Modex's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus.

Representing BMS on its in-license from Rockefeller University of monoclonal antibodies for the treatment of COVID-19

Representing Gilead Sciences and Kite Pharma in a collaboration and license arrangement with oNKO-Innate to develop next-generation drug and engineered cell therapies focused on natural killer cells.

Representing Gilead Sciences in its collaboration with Yuhan Corporation to co-develop novel therapeutics for patients with advanced fibrosis due to NASH.

Representing Incyte Corporation in its license and collaboration agreement with MacroGenics relating to an anti-PD-1 antibody.

Representing multiple pharmaceutical companies and diagnostics manufacturers in collaboration agreements to develop companion diagnostics for drug products.

IP Rights in Transactions

Technology Contracts

Medical Devices

Pharmaceuticals and Biotechnology

Cell, Tissue, and Gene Therapies

Licensing and Commercial Transactions

Education and admissions

Education

J.D., Harvard Law School, 2000

B.A., University of Virginia, with distinction, Phi Beta Kappa, 1997

Memberships

Member, American Bar Association

Member, Virginia Bar Association

Bar admissions and qualifications

Virginia

Representing Regeneron in a genomics collaboration with Geisinger Health Systems.

Representing Helsinn Healthcare in connection with license and collaboration agreements with MEI Pharma and Taiho Pharmaceuticals.

Representing Cormedix in various license, collaboration, supply, and distribution agreements relating to its Neutrolin product.

Representing Daiichi Sankyo in its co-commercialization agreement with AstraZeneca relating to MOVANTIK in the United States.

Representing Novartis in the sale of its animal health business to Eli Lilly for approximately US\$5.4bn.

Awards and rankings

- IP Star - Transactions, *Managing IP*, 2023
- Shortlisted for Licensing and Collaboration Attorney of the Year, *LMG Life Sciences*, 2022
- Ranked Practitioner, Licensing and Collaborations, *LMG Life Sciences*, 2022
- Practitioner of the Year (IP Transactions), *Managing IP*, 2021
- Media, Technology, and Telecoms: Technology Transactions, *Legal 500 US*, 2019
- BTI Client Service All-Star, *BTI Consulting Group*, 2017
- Rising Star, *Virginia Super Lawyers*, 2008, 2010, 2015, 2019
- Rising Star, *Washington, D.C. Super Lawyers*, 2015
- Intellectual Property, *Virginia Legal Elite*, 2011
- Young Lawyer, *Virginia Legal Elite*, 2010
- Health Law, *Virginia Legal Elite*, 2009

Latest thinking and events

- Press releases
 - Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and

a US\$69 million follow-on public offering of equity securities

- Hogan Lovells Events
 - Hogan Lovells APAC Life Sciences and Health Care Webinar Series - Spotlight on the U.S. - Session 2
- Press releases
 - Hogan Lovells advises Omega Therapeutics on research collaboration transaction with Novo Nordisk and Flagship Pioneering
- Hogan Lovells Events
 - J.P. Morgan Healthcare Conference
- Press releases
 - Hogan Lovells advises Daiichi Sankyo on global multi-ADC collaboration
- News
 - Horizons 2023: Panelists discuss key issues keeping APAC life sciences GCs up at night